Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Imugene is currently preparing to release capital raising details.
The company is developing HER-2+ gastric and breast cancer immunotherapies.
The halt will remain in place until the opening of trade on Wednesday 9th September 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.